Skip to content

SYNERGY PHARMACEUTICALS, INC.: 10-Q filed 2012-05-10

What SYNERGY PHARMACEUTICALS, INC. reported in its quarterly report filed 2012-05-10 (fiscal Q1 2012): 26 published measures, 73 facts as tagged in accession 0001104659-12-035825.

This filing

Form
10-Q (quarterly report)
Filed
2012-05-10
Fiscal period
fiscal Q1 2012
Accession
0001104659-12-035825 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All SYNERGY PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-03-319,579,828USD
At 2011-12-3115,869,539USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2012-03-316,366,975USD
At 2011-12-316,072,113USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-03-313,212,853USD
At 2011-12-319,797,426USD
At 2010-12-31-4,099,388USD
At 2009-12-317,483,768USD
At 2008-12-31-1,155,792USD
At 2007-12-31-11,268USD
At 2006-12-31-118USD
At 2005-12-3120,084USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-03-316,123,340USD
At 2011-12-3113,244,883USD
At 2011-03-31938,700USD
At 2010-12-311,707,516USD

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-6,843,341USD91
2005-11-15 to 2012-03-31-49,927,344USD2329
2011-01-01 to 2011-03-31-3,003,836USD90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2005-11-15 to 2012-03-3112,195USD2329

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2005-11-15 to 2012-03-3158,037,863USD2329
2011-01-01 to 2011-03-312,115,000USD90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-278,202USD91
2005-11-15 to 2012-03-31-1,987,179USD2329
2011-01-01 to 2011-03-31120,020USD90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-03-31-76,631,662USD
At 2011-12-31-69,609,018USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-01-01 to 2012-03-3154,298,079shares91
2011-01-01 to 2011-03-3146,167,416shares90

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2012-01-01 to 2012-03-3154,298,079shares91
2011-01-01 to 2011-03-3146,167,416shares90

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2012-03-315,279USD
At 2011-12-315,773USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-03-31438,071USD91
2005-11-15 to 2012-03-313,406,720USD2329
2011-01-01 to 2011-03-31147,460USD90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-7,069,268USD91
2005-11-15 to 2012-03-31-83,283,566USD2329
2011-01-01 to 2011-03-31-3,375,752USD90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-03-317,740,866USD
At 2011-12-3114,308,285USD

Interest expense

Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.

PeriodValueUnitDays
2005-11-15 to 2012-03-3111,877USD2329
2011-01-01 to 2011-03-3111,877USD90

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-03-313,049,807USD
At 2011-12-312,746,999USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2012-03-312,084,471USD
At 2011-12-311,415,617USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2012-03-3154,306,156shares
At 2011-12-3154,279,906shares

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2012-03-31965,336USD
At 2011-12-311,331,382USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-03-311,617,526USD
At 2011-12-311,063,402USD

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2012-01-01 to 2012-03-31-7,022,644USD91
2005-11-15 to 2012-03-31-76,631,662USD2329
2011-01-01 to 2011-12-31-14,467,036USD365
2011-01-01 to 2011-03-31-3,702,280USD90
2010-01-01 to 2010-12-31-15,221,441USD365
2009-01-01 to 2009-12-31-8,125,100USD365
2008-01-01 to 2008-12-31-31,755,180USD366
2007-01-01 to 2007-12-31-20,043USD365
2006-01-01 to 2006-12-31-20,202USD365
2005-11-16 to 2005-12-31-16USD46

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-01-01 to 2012-03-311,731,128USD91
2005-11-15 to 2012-03-3121,375,770USD2329
2011-01-01 to 2011-03-311,897,626USD90

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-03-31494USD91
2005-11-15 to 2012-03-317,644USD2329
2011-01-01 to 2011-03-31494USD90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-01-01 to 2012-03-3146,624USD91
2005-11-15 to 2012-03-316,723,725USD2329
2011-01-01 to 2011-03-31-326,528USD90

Proceeds from issuing common stock

Cash received from issuing common stock during the period. It is gross of costs only where the filer reports it so, and it does not include noncash issuances.

PeriodValueUnitDays
2005-11-15 to 2012-03-312,000USD2329

Inspect the source

Entity
SYNERGY PHARMACEUTICALS, INC. / CIK 0001347613
Captured
SEC response SHA-256
60ac23b596d48b74d11ecee665bf68a808f9daca8c63f598b6849064bbbad449

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001347613.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))